PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community remains optimistic for a cure or disease modifying treatment for Alzheimer’s, with particular faith in the amyloid hypothesis. Industry, advocacy groups, academia, and many other stakeholders in clinical development continue to embrace new technologies and data science with the hope that one day these will contribute toward bringing treatments to the right patients at the right stage of the disease.
Introduction to Patient Feasibility
Patient Feasibility is an area under-explored in the clinical trial industry. Currently, protocol and site feasibility are the primary methods of…
Site Commercial Solutions
Our Site Commercial Solutions are comprehensive, end-to-end commercial management solutions built directly into your trial.
Cross-Border Enrollment of Rare Disease Patients
Clinical trials in rare diseases present unique challenges unseen in trials for more common conditions. Cross-border enrollment can be key to…